Navigation Links
ENDEAVOR IV achieves primary endpoint, demonstrates similar safety profile compared to Taxus stent

WASHINGTON, DC OCTOBER 22, 2007 Late-breaking results from the ENDEAVOR IV trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting stent met the trials primary endpoint, demonstrating a similar overall safety profile (equivalent rates of death, heart attack, and repeat procedures) to the Taxus paclitaxel-eluting stent at 1 year.

In addition, the Endeavor stent showed a lower rate of less-severe (non-Q-wave) heart attacks at 30 days, but a higher rate of angiographic late loss (artery re-narrowing) at eight months compared to the Taxus stent.

The primary endpoint of the trial, non-inferiority as measured by target vessel failure (TVF) between the two stents, was met, said Martin B. Leon, MD, Founder and Chairman Emeritus, CRF and Professor of Medicine at Columbia University Medical Center. TVF occurred in 6.6 percent of patients receiving the Endeavor stent and 7.2 percent of patients receiving the Taxus stent, a difference that was not statistically significant. The Endeavor stent also demonstrated equivalence to Taxus in several long term measures.

At 12 months, the difference between the rates of target lesion revascularization with the Endeavor (4.5 percent) and Taxus (3.2 percent) stents was not statistically significant. Likewise, target vessel revascularization rates at 12 months were also similar (6.3 percent with Endeavor vs. 6.7 percent with Taxus).

Interestingly, at 30 days, rates of less-severe heart attacks were 0.5 percent with Endeavor compared with 2.2 percent with Taxus, a statistically significant difference. Late loss at eight months, meanwhile, was significantly greater with Endeavor (0.67 mm) compared with Taxus (0.42 mm).

Importantly, in the diabetic subset of 477 patients, Endeavor had similar efficacy compared with Taxus including target lesion revascularization and in-segment restenosis.

The Endeavor IV trial included 1,548 patients at 80 locations and was randomized to treatment with either the Endeavor or Taxus stent.


Contact: David Harrison
Cardiovascular Research Foundation

Related medicine news :

1. ENDEAVOR III Trial Reports Key Findings on New-generation Stent
2. Human Genome Project Achieves Technological Triumph
3. A Village in Madhya Pradesh Achieves Total Sanitation
5. Is caries in primary and permanent tooth related?
6. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
7. Shortage Of Funds In Primary Care Trust In UK
8. What Will Primary Care Look Like In England by 2015?
9. Primary Health Care MoU Signed on the Sidelines of the PBD
10. Primary Care centers to provide out patient treatment
11. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
Post Your Comments:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. ... magazine’s Code Talker Award, an essay contest in which patients and their families pay ... be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology: